Literature DB >> 12427879

Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias.

C Goizet1, G Lesca, A Dürr.   

Abstract

OBJECTIVE: To report a 7-year experience of presymptomatic testing in persons at risk for Huntington disease (HD) and to compare their characteristics and outcomes with those of persons at risk for a less disabling condition, autosomal dominant cerebellar ataxias (ADCA).
METHODS: The authors collected data on presymptomatic testing for HD (n = 712) and ADCA (n = 46) in 10 French centers.
RESULTS: The characteristics of applicants were similar in HD and ADCA, revealing a predominance of women, a low rate of completing the presymptomatic testing program, and a high rate of follow-up. The frequency of serious events was low (2% for HD, 5% for ADCA), but such events were also found after favorable results. Family planning was a more frequent reason for seeking presymptomatic testing in ADCA than in HD. Prenatal diagnosis was performed in only half of the pregnancies in HD carriers (n = 35) but in all of those in ADCA carriers (n = 4).
CONCLUSION: Counseling in multistep and multidisciplinary teams is important not only for presymptomatic testing in HD but also for less disabling diseases.

Entities:  

Mesh:

Year:  2002        PMID: 12427879     DOI: 10.1212/01.wnl.0000032255.75650.c2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing.

Authors:  Caroline Santa Maria Rodrigues; Viviane Ziebell de Oliveira; Gabriela Camargo; Claudio Maria da Silva Osório; Raphael Machado de Castilhos; Maria Luiza Saraiva-Pereira; Lavínia Schuler-Faccini; Laura Bannach Jardim
Journal:  J Genet Couns       Date:  2011-06-30       Impact factor: 2.537

2.  The ever expanding spinocerebellar ataxias. Editorial.

Authors:  Antoni Matilla-Dueñas
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

3.  22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium.

Authors:  Sheharyar S Baig; Mark Strong; Elisabeth Rosser; Nicola V Taverner; Ruth Glew; Zosia Miedzybrodzka; Angus Clarke; David Craufurd; Oliver W Quarrell
Journal:  Eur J Hum Genet       Date:  2016-05-11       Impact factor: 4.246

Review 4.  Ethical issues in neurogenetics.

Authors:  Wendy R Uhlmann; J Scott Roberts
Journal:  Handb Clin Neurol       Date:  2018

5.  Analysis of the Reasons for Non-Uptake of Predictive Testing for Huntington's Disease in Spain: A Qualitative Study.

Authors:  Jesús Rivera-Navarro; Esther Cubo; Natividad Mariscal
Journal:  J Genet Couns       Date:  2015-04-30       Impact factor: 2.537

6.  Prenatal testing in Huntington disease: after the test, choices recommence.

Authors:  Hanane Bouchghoul; Stéphane-Françoise Clément; Danièle Vauthier; Cécile Cazeneuve; Sandrine Noel; Marc Dommergues; Delphine Héron; Jacky Nizard; Marcela Gargiulo; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2016-06-15       Impact factor: 4.246

7.  Problems assessing uptake of Huntington disease predictive testing and a proposed solution.

Authors:  Roslyn J Tassicker; Betty Teltscher; M Kaye Trembath; Veronica Collins; Leslie J Sheffield; Edmond Chiu; Lyle Gurrin; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2008-07-30       Impact factor: 4.246

8.  Decreasing uptake of predictive testing for Huntington's disease in a German centre: 12 years' experience (1993-2004).

Authors:  Christiane Bernhardt; Anne-Marie Schwan; Peter Kraus; Joerg Thomas Epplen; Erdmute Kunstmann
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

Review 9.  Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges.

Authors:  John M Ringman; Joshua Grill; Yaneth Rodriguez-Agudelo; Mireya Chavez; Chengjie Xiong
Journal:  Alzheimers Dement       Date:  2009-03       Impact factor: 21.566

10.  Role of the disease in the psychological impact of pre-symptomatic testing for SCA2 and FAP ATTRV30M: Experience with the disease, kinship and gender of the transmitting parent.

Authors:  Milena Paneque; Carolina Lemos; Alda Sousa; Luis Velázquez; Manuela Fleming; Jorge Sequeiros
Journal:  J Genet Couns       Date:  2009-10       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.